Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857220 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT00857220 is a Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 304 participants, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00857220, a Phase 3 study of Insomnia and Attention Deficit Hyperactivity Disorder, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Conditions Studied
Interventions
- DRUG eszopiclone
Study Locations (20)
California
- AV Institute, Inc. - Carson
- Clinical Innovations, Inc. - Costa Mesa
- Behavioral Research Specialists, LLC - Glendale
- Sun Valley Research Center - Imperial
- Excell Research, Inc. - Oceanside
- North County Clinical Research (NCCR) - Oceanside
- Pacific Clinical Research Medical Group - Orange
- SDS Clinical Trials, Inc. - Orange
- Clinical Innovations, Inc. - Riverside
- Artemis Institute for Clinical Research - San Diego
- Clinical Innovations - San Diego
- Neuropsychiatric Research Center of Orange County - Santa Ana
- Apex Research Institute - Santa Ana
- Clinical Innovations, Inc. - Santa Ana
- Elite Clinical Trials, Inc. - Wildomar
Florida
- Sarkis Clinical Trials - Gainesville
- MD Clinical - Hallandale
Arizona
- REM Medical Clinical Research - Tucson
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- Delta Waves, Inc. - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857220
The ClinicalTrials.gov registry entry for NCT00857220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (81% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which eszopiclone is the first listed.
NCT00857220 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00857220 about?
NCT00857220 is a clinical study titled "Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia". A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
What is the current status of trial NCT00857220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2009-05. Estimated completion is 2011-10.
What conditions does trial NCT00857220 study?
This clinical trial studies the following conditions: Insomnia, Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00857220?
The interventions under investigation include: eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00857220?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00857220 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
RECRUITING · Phase 3
-
National Adaptive Trial for PTSD Related Insomnia
ACTIVE NOT RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
COMPLETED · Phase 3
-
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
RECRUITING
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.